Articles related to RETINA

CPT code 0936T became active in January 2025 for retinal photobiomodulation, with reimbursement determined claim-by-claim and scope-of-practice limits restricting who may perform the procedure.

Early trials suggest red‑light therapy may slow pediatric myopia progression, but unanswered questions around long‑term retinal safety and clinical positioning remain.

Vigabatrin can cause irreversible peripheral retinal toxicity that is often asymptomatic, underscoring the need for consistent ophthalmic monitoring in treated patients.

FDA approval of 20‑week dosing for Eylea HD offers eligible wAMD and DME patients the potential for fewer injections while maintaining long‑term visual outcomes.

According to Elizabeth Cifers, MBA, a practice management consultant specializing in retina practice: “The key is to focus on medical necessity for the information the test will provide, rather than ordering an OCTA routinely.”

“This acquisition immediately advances Biogen’s ongoing transformation… with two approved, best-in-class medicines that complement our existing portfolio.”
— Christopher Viehbacher, President and CEO, Biogen